Osteoarthritis is one of the most common musculoskeletal disorders that significantly impact the quality of life of people suffering from it. It is known to be a chief cause of pain, loss of function and disability, and requires medical intervention. The various treatment approaches used for managing knee OA comprises both pharmacological and non-pharmacological modalities.
A 800 mg/day pharmaceutical-grade Chondroitin sulphate was found to be better than placebo and similar to celecoxib in alleviating pain and enhancing function in patients with symptomatic knee osteoarthritis (OA) over 6 months.
Ankylosing spondylitis (AS) is a chronic immune-mediated inflammatory disease with worldwide prevalence of about 0.2–1.4%. The advancement of AS may result in structural damage of the spine, worsening of joint function, physical disability, and significant functional impairment, culminating in reduced health related quality of life (HRQoL).
The initiation of recurrent methotrexate (MTX) and various biologic agents has had such an influence on the treatment of rheumatoid arthritis (RA) that a standard shift has appeared towards earlier and more aggressive involvement with the goal of remission.
Polycystic Ovarian Syndrome (PCOS) is one of the most common endocrinopathies in women of reproductive age, with incidences ranging between 4–20%. It is characterized by menstrual and ovulatory dysfunction, infertility, hirsutism and increased cardiovascular risk factors. All these factors can negatively affect the health-related quality of life (HRQOL).
The most usual form of inflammatory arthritis is gout. As per the recent guidelines, a xanthine oxidase inhibitor as urate-lowering therapy (ULT) must be recommended to bring serum uric acid (SUA) to the target range of < 6 mg/dL
- 1 of 20